Key statistics dashboard for Predictive Oncology Inc. (POAI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline.
Stock Data
| Price | $4.91 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.03 |
| Price / Book | 2.84 |
| P/S | 1.09 |
| P/FCF | -0.69 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 7.15% |
| EBIT Margin | -7243.86% |
| EBITDA Margin | -7759.17% |
| Operating Margin | -1483.87% |
| Net Margin | -7242.42% |
Financial Health
| Current Ratio | 1.45 |
| Quick Ratio | 1.45 |
| Cash Ratio | 0.57 |
| Debt / Equity | 0.04 |
| Debt / Assets | 1.24% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 2.62 |
Per-Share Data
| Revenue per share | 0.17 |
| Book Value per share | 1.73 |
| Cash per share | 1.11 |
| FCF per share | -0.26 |
| Tangible Book Value per share | 1.73 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 0.00 |
Related companies: AIM · AMIX · BNGO · CYCN · GBS · HSCS · KTTA
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of POAI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks